<p>/PRNewswire/ -- 罗森律师事务所是一家全球投资者权益律师事务所，提醒在 2023 年 6 月 5 日至 2025 年 12 月 26 日期间（“集体诉讼期间”）购买了 Mereo BioPharma Group plc（纳斯达克代码：MREO）美国存托股票（“ADS”）的投资者，注意 2026 年 4 月 6 日的重要首席原告截止日期。</p>
<p>那么，如何处理：如果您在集体诉讼期间购买了 Mereo ADS，您可能有权在不支付任何自付费用或成本的情况下通过风险代理安排获得赔偿。</p>
<p>接下来该做什么：要加入 Mereo 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=52452 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。集体诉讼已经提起。如果您希望担任首席原告，必须在 2026 年 4 月 6 日之前向法院提出申请。首席原告是代表其他集体成员指导诉讼的代表方。</p>
<p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色中有成功记录的合格律师事务所。通常，发布通知的公司没有可比的经验、资源或任何有意义的同行认可。这些公司中的许多实际上并不处理证券集体诉讼，而只是作为中介，转介客户或与实际诉讼案件的律师事务所合作。选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾获得针对中国公司的最大证券集体诉讼和解。该事务所于 2017 年被 ISS 证券集体诉讼服务评选为证券集体诉讼和解数量第一。自 2013 年以来，该事务所每年都排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者争取了超过 4.38 亿美元。2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师获得了 Lawdragon 和 Super Lawyers 的认可。</p>
<p>案件详情：根据诉讼，被告向投资者提供了有关其在成骨不全（OI）中对 setrusumab 的第三阶段 Orbit 和 COSMIC 研究的预期结果的重要信息。被告的声明包括对 setrusumab 最终能够减少受试患者年化骨折率的信心，以及在研究中使 setrusumab 有机会在这一关键终点上达到统计显著性的信心。</p>
<p>诉讼声称，被告在向投资者提供这些积极声明的同时，传播了虚假和具有实质误导性的声明和/或隐瞒了有关第三阶段 ORBIT 和 COSMIC 项目真实状态的重大不利事实；这两个项目均未达到减少年化临床骨折率的主要终点，与安慰剂或双膦酸盐对照组相比。缺乏这些重要事实的声明导致投资者以人为抬高的价格购买了 Mereo 的 ADS。当真实细节进入市场时，诉讼声称投资者遭受了损失。</p>
<p>要加入 Mereo 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=52452 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
<p>尚未认证集体。直到集体被认证，您都没有律师代表，除非您聘请一位。您可以选择自己选择的律师。您也可以保持缺席集体成员身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任首席原告。</p>
<p>请关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/。</p>
<p>律师广告。以往的结果并不保证类似的结果。</p>
<p>联系信息：</p>
<p>Laurence Rosen 律师。</p>
<p>Phillip Kim 律师。</p>
<p>罗森律师事务所，P.A.。</p>
<p>275 Madison Avenue, 40th Floor</p>
<p>纽约，NY 10016</p>
<p>电话：(212) 686-1060</p>
<p>免费电话：(866) 767-3653</p>
<p>传真：(212) 202-3827</p>
<p>[email protected]</p>
<p>www.rosenlegal.com</p>
<p>来源：罗森律师事务所，P.A.。</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzEwJk5ld3NJdGVtSWQ9REMwNzE0MSZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMTAxOTExUFJfTkVXU19VU1BSX19fX19EQzA3MTQx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzEwJk5ld3NJdGVtSWQ9REMwNzE0MSZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMTAxOTExUFJfTkVXU19VU1BSX19fX19EQzA3MTQx"/></p>

MREO

<p>罗森律师事务所提醒在 2023 年 6 月 5 日至 2025 年 12 月 26 日期间购买了 Mereo BioPharma Group plc（纳斯达克代码：MREO）美国存托股票的投资者，关于一起与证券欺诈相关的集体诉讼。投资者可能有权获得无需预付费用的赔偿。作为主要原告的截止日期为 2026 年 4 月 6 日。诉讼指控 Mereo 误导投资者关于 setrusumab 的第三阶段研究，导致股价虚高。感兴趣的各方可以联系该事务所以获取更多信息</p>

<p>, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (&#34;ADS&#34;) of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025 (the &#34;Class Period&#34;), of the important April 6, 2026 lead plaintiff deadline.</p>
<div class="lb-trans"><p>/PRNewswire/ -- 罗森律师事务所是一家全球投资者权益律师事务所，提醒在 2023 年 6 月 5 日至 2025 年 12 月 26 日期间（“集体诉讼期间”）购买了 Mereo BioPharma Group plc（纳斯达克代码：MREO）美国存托股票（“ADS”）的投资者，注意 2026 年 4 月 6 日的重要首席原告截止日期。</p>
</div><p>So What: If you purchased Mereo ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.</p>
<div class="lb-trans"><p>那么，如何处理：如果您在集体诉讼期间购买了 Mereo ADS，您可能有权在不支付任何自付费用或成本的情况下通过风险代理安排获得赔偿。</p>
</div><p>What to do next: To join the Mereo class action, go to https://rosenlegal.com/submit-form/?case_id=52452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p>
<div class="lb-trans"><p>接下来该做什么：要加入 Mereo 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=52452 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。集体诉讼已经提起。如果您希望担任首席原告，必须在 2026 年 4 月 6 日之前向法院提出申请。首席原告是代表其他集体成员指导诉讼的代表方。</p>
</div><p>Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.</p>
<div class="lb-trans"><p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色中有成功记录的合格律师事务所。通常，发布通知的公司没有可比的经验、资源或任何有意义的同行认可。这些公司中的许多实际上并不处理证券集体诉讼，而只是作为中介，转介客户或与实际诉讼案件的律师事务所合作。选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾获得针对中国公司的最大证券集体诉讼和解。该事务所于 2017 年被 ISS 证券集体诉讼服务评选为证券集体诉讼和解数量第一。自 2013 年以来，该事务所每年都排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者争取了超过 4.38 亿美元。2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师获得了 Lawdragon 和 Super Lawyers 的认可。</p>
</div><p>Details of the case: According to the lawsuit, defendants provided investors with material information concerning their expected results for the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately reduce the annualized fracture rates of the tested patients and in the study itself to put setrusumab in an opportunity to succeed in reaching statistical significance of this key endpoint.</p>
<div class="lb-trans"><p>案件详情：根据诉讼，被告向投资者提供了有关其在成骨不全（OI）中对 setrusumab 的第三阶段 Orbit 和 COSMIC 研究的预期结果的重要信息。被告的声明包括对 setrusumab 最终能够减少受试患者年化骨折率的信心，以及在研究中使 setrusumab 有机会在这一关键终点上达到统计显著性的信心。</p>
</div><p>The defendants, the lawsuit claims, provided these positive statements to investors while, at the same time, disseminating false and materially misleading statements and/or concealing material adverse facts concerning the true state of the Phase 3 ORBIT and COSMIC programs; neither of which hit their primary endpoints of reducing annualized clinical fracture rate compared to the placebo or bisphosphonate control groups, respectively. Such statements absent these material facts caused investors to purchase Mereo's ADSs at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.</p>
<div class="lb-trans"><p>诉讼声称，被告在向投资者提供这些积极声明的同时，传播了虚假和具有实质误导性的声明和/或隐瞒了有关第三阶段 ORBIT 和 COSMIC 项目真实状态的重大不利事实；这两个项目均未达到减少年化临床骨折率的主要终点，与安慰剂或双膦酸盐对照组相比。缺乏这些重要事实的声明导致投资者以人为抬高的价格购买了 Mereo 的 ADS。当真实细节进入市场时，诉讼声称投资者遭受了损失。</p>
</div><p>To join the Mereo class action, go to https://rosenlegal.com/submit-form/?case_id=52452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.</p>
<div class="lb-trans"><p>要加入 Mereo 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=52452 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
</div><p>No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.</p>
<div class="lb-trans"><p>尚未认证集体。直到集体被认证，您都没有律师代表，除非您聘请一位。您可以选择自己选择的律师。您也可以保持缺席集体成员身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任首席原告。</p>
</div><p>Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.</p>
<div class="lb-trans"><p>请关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/。</p>
</div><p>Attorney Advertising. Prior results do not guarantee a similar outcome.</p>
<div class="lb-trans"><p>律师广告。以往的结果并不保证类似的结果。</p>
</div><p>Contact Information:</p>
<div class="lb-trans"><p>联系信息：</p>
</div><p>Laurence Rosen, Esq.</p>
<div class="lb-trans"><p>Laurence Rosen 律师。</p>
</div><p>Phillip Kim, Esq.</p>
<div class="lb-trans"><p>Phillip Kim 律师。</p>
</div><p>The Rosen Law Firm, P.A.</p>
<div class="lb-trans"><p>罗森律师事务所，P.A.。</p>
</div><p>275 Madison Avenue, 40th Floor</p>
<div class="lb-trans"><p>275 Madison Avenue, 40th Floor</p>
</div><p>New York, NY 10016</p>
<div class="lb-trans"><p>纽约，NY 10016</p>
</div><p>Tel: (212) 686-1060</p>
<div class="lb-trans"><p>电话：(212) 686-1060</p>
</div><p>Toll Free: (866) 767-3653</p>
<div class="lb-trans"><p>免费电话：(866) 767-3653</p>
</div><p>Fax: (212) 202-3827</p>
<div class="lb-trans"><p>传真：(212) 202-3827</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>www.rosenlegal.com</p>
<div class="lb-trans"><p>www.rosenlegal.com</p>
</div><p>SOURCE THE ROSEN LAW FIRM, P. A.</p>
<div class="lb-trans"><p>来源：罗森律师事务所，P.A.。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzEwJk5ld3NJdGVtSWQ9REMwNzE0MSZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMTAxOTExUFJfTkVXU19VU1BSX19fX19EQzA3MTQx" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC07141&amp;Transmission_Id=202603101911PR_NEWS_USPR_____DC07141&amp;DateId=20260310"/></p>

MREO 投资者有机会主导 Mereo BioPharma Group plc 的证券欺诈诉讼